56. ベーチェット病 [臨床試験数:68,薬物数:87(DrugBank:31),標的遺伝子数:36,標的パスウェイ数:113

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR19000271472020-01-012019-11-02Efficacy and safety of adalimumab in Behcet's disease-related uveitisEfficacy and safety of adalimumab in Behcet's disease-related uveitis Behcet's disease-related uveitis1:Adalimumab;State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen UniversityNULLPendingBoth1:30;China
2JPRN-UMIN0000124692013/12/0202/12/2013Comparison of Adalimumab and Steroid in Intestinal Behcet's diseaseComparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study Intestinal Behcet's diseaseSubcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously.
Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately
Castle Study GroupNULLRecruiting15years-oldNot applicableMale and Female50Not selectedJapan
3NCT01243671October 201017/11/2010A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's DiseaseA Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's DiseaseIntestinal Behçet's DiseaseBiological: AdalimumabAbbVie (prior sponsor, Abbott)Eisai Co., Ltd.Completed15 YearsN/AAll20Phase 3Japan